Organogenesis (ORGO) Expected to Announce Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will likely be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $109.60 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Organogenesis Stock Performance

Shares of ORGO opened at $3.18 on Tuesday. The stock has a 50 day moving average of $3.38 and a 200 day moving average of $3.21. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis has a 12 month low of $2.16 and a 12 month high of $4.57. The company has a market capitalization of $399.81 million, a price-to-earnings ratio of -53.00 and a beta of 1.77.

Insider Transactions at Organogenesis

In related news, CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $3.36, for a total transaction of $186,866.40. Following the completion of the transaction, the chief executive officer now owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This represents a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 278,116 shares of company stock worth $991,190 in the last ninety days. Company insiders own 36.90% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.